Why the study?
The impact of type 2 myocardial infarction (T2MI) on outcomes in patients hospitalized with COVID-19 was not well studied.
Does Type 2 myocardial infarction increase the risk of in-hospital mortality and adverse cardiovascular events in patients hospitalized with COVID-19?
Does Type 2 myocardial infarction increase the risk of in-hospital mortality and adverse cardiovascular events in patients hospitalized with COVID-19?
Type 2 myocardial infarction in hospitalized COVID-19 patients is associated with significantly increased risks of in-hospital mortality, sudden cardiac arrest, and cardiogenic shock.
Answers are grounded in this paper and cite their sources.
T2MI signals higher in-hospital mortality and shock risk in COVID-19; leaves open whether targeted strategies improve outcomes.
Background Myocardial infarction Type II (T2MI) is a prevalent cause of troponin elevation secondary to a variety of conditions causing stress/demand mismatch. The impact of T2MI on outcomes in patients hospitalized with COVID-19 is not well studied.Methods The Nationwide Inpatient Sample database from the year 2020 was queried to identify COVID-19 patients with T2MI during the index hospitalization. Clinical Modification (ICD-10-CM) codes ‘U07.1’ and ‘I21.A1’ were used as disease identifiers for COVID-19 and T2MI respectively. Multivariate adjusted Odds ratio (aOR) and propensity score matching (PSM) was done to compare outcomes among COVID patients with and without T2MI. The primary outcome was in-hospital mortality.Results A total of 1,678,995 COVID-19-weighted hospitalizations were identified in the year 2020, of which 41,755 (2.48%) patients had T2MI compared to 1,637,165 (97.5%) without T2MI. Patients with T2MI had higher adjusted odds of in-hospital mortality (aOR 1.44, PSM 32.27%, 95% CI 1.34–1.54) sudden cardiac arrest (aOR 1.29, PSM 6.6%, 95% CI 1.17–1.43) and CS (aOR 2.16, PSM 2.73%, 95% CI 1.85–2.53) compared to patients without T2MI. The rate of coronary angiography (CA) in T2MI with COVID was 1.19%, with significant use of CA among patients with T2MI complicated by CS compared to those without CS (4% vs 1.1%, p < 0.001). Additionally, COVID-19 patients with T2MI had an increased prevalence of sepsis compared to COVID-19 without T2MI (48% vs 24.1%, p < 0.001).Conclusion COVID-19 patients with T2MI had worse cardiovascular outcomes with significantly higher in-hospital mortality, SCA, and CS compared to those without T2MI. Long-term mortality and morbidity among COVID-19 patients who had T2MI will need to be clarified in future studies.
No takes yet. Share an insight, caveat, or question.
Sattar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: